CL2021001532A1 - Rutas lineales en fase de solución para hexapéptidos de wnt - Google Patents

Rutas lineales en fase de solución para hexapéptidos de wnt

Info

Publication number
CL2021001532A1
CL2021001532A1 CL2021001532A CL2021001532A CL2021001532A1 CL 2021001532 A1 CL2021001532 A1 CL 2021001532A1 CL 2021001532 A CL2021001532 A CL 2021001532A CL 2021001532 A CL2021001532 A CL 2021001532A CL 2021001532 A1 CL2021001532 A1 CL 2021001532A1
Authority
CL
Chile
Prior art keywords
wnt
hexapeptides
linear solution
pathways
phase
Prior art date
Application number
CL2021001532A
Other languages
English (en)
Inventor
Rao Kamaraju Raghavendra
Dennis Henriksen
Pratap Tadikonda Veerabhadra
Original Assignee
Wntresearch Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wntresearch Ab filed Critical Wntresearch Ab
Publication of CL2021001532A1 publication Critical patent/CL2021001532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/063—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha-amino functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere, en general, al campo de la síntesis de polipéptidos y más particularmente, a una síntesis lineal en fase de solución del hexapéptido de Wnt Foxy-5 y a derivados protegidos y fragmentos peptídicos del mismo.
CL2021001532A 2018-12-14 2021-06-10 Rutas lineales en fase de solución para hexapéptidos de wnt CL2021001532A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18212658.1A EP3666789A1 (en) 2018-12-14 2018-12-14 Linear solution phase routes for wnt hexapeptides

Publications (1)

Publication Number Publication Date
CL2021001532A1 true CL2021001532A1 (es) 2021-12-31

Family

ID=65010407

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001532A CL2021001532A1 (es) 2018-12-14 2021-06-10 Rutas lineales en fase de solución para hexapéptidos de wnt

Country Status (17)

Country Link
US (1) US20220017568A1 (es)
EP (2) EP3666789A1 (es)
JP (1) JP7362148B2 (es)
KR (1) KR20210112331A (es)
CN (1) CN113646324B (es)
AU (1) AU2019395708A1 (es)
BR (1) BR112021011318A2 (es)
CA (1) CA3123331C (es)
CL (1) CL2021001532A1 (es)
DK (1) DK3894426T3 (es)
ES (1) ES2934161T3 (es)
FI (1) FI3894426T3 (es)
HU (1) HUE061310T2 (es)
MX (1) MX2021006809A (es)
PL (1) PL3894426T3 (es)
SG (1) SG11202105965PA (es)
WO (1) WO2020120198A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4176901T3 (pl) 2021-12-10 2024-04-08 Wntresearch Ab Stabilne kompozycje heksapeptydu foxy-5 o wysokiej rozpuszczalności zawierające zasadę azotową

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2384763B1 (en) 2005-05-30 2015-04-29 Wntresearch AB A peptide ligand to impair cancer cell migration
US20110124574A1 (en) * 2008-04-30 2011-05-26 Tommy Andersson Restoration of estrogen receptor-(alpha) activity
RU2517190C2 (ru) * 2008-08-13 2014-05-27 Внтрисерч Аб Применение производных пептида wnt5-a для лечения меланомы и рака желудка
AU2015359043C1 (en) * 2014-12-10 2022-01-06 Hyperstem, SA Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
CN105111303B (zh) * 2015-06-23 2019-07-26 济南康和医药科技有限公司 一种固液结合制备利拉鲁肽的方法
EP3613757A1 (en) * 2018-08-20 2020-02-26 Wntresearch AB Solution phase routes for wnt hexapeptides

Also Published As

Publication number Publication date
ES2934161T3 (es) 2023-02-17
JP7362148B2 (ja) 2023-10-17
DK3894426T3 (da) 2022-12-19
US20220017568A1 (en) 2022-01-20
AU2019395708A1 (en) 2021-06-24
WO2020120198A8 (en) 2021-10-28
EP3666789A1 (en) 2020-06-17
SG11202105965PA (en) 2021-07-29
JP2022513474A (ja) 2022-02-08
CA3123331C (en) 2023-12-05
BR112021011318A2 (pt) 2021-11-30
FI3894426T3 (fi) 2023-01-13
CN113646324A (zh) 2021-11-12
EP3894426A1 (en) 2021-10-20
WO2020120198A1 (en) 2020-06-18
CA3123331A1 (en) 2020-06-18
MX2021006809A (es) 2021-08-24
HUE061310T2 (hu) 2023-06-28
CN113646324B (zh) 2024-03-29
KR20210112331A (ko) 2021-09-14
EP3894426B1 (en) 2022-09-21
PL3894426T3 (pl) 2023-03-13

Similar Documents

Publication Publication Date Title
ECSP18082207A (es) Neoantígenos y métodos de su uso
DK3778621T3 (da) Peptidsyntesefremgangsmåde
UA118167C2 (uk) Пептид та його застосування
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
SG10201805806RA (en) Modulation of Structured Polypeptide Specificity
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
CY1125043T1 (el) Ενωση τριπεπτιδιο, μεθοδος παρασκευης αυτης, και εφαρμογη αυτης
BR112015022856A8 (pt) inibidores de protease de cetona de epóxi de tripeptídeo e dipeptídeo
CO6680702A2 (es) Péptido o complejo péptido que se une a integrina alfa 2 y metodos y sus usos que implican a los mismos
CO6331291A2 (es) Peptidos de señalizacion de la crkl
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
AR100134A1 (es) Métodos y composiciones de administración tópica para el cuidado de la piel
WO2017112809A8 (en) System and method for solution phase gap peptide synthesis
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
CL2021001532A1 (es) Rutas lineales en fase de solución para hexapéptidos de wnt
ES2570458T3 (es) Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7
BR112016013157A2 (pt) peptídeos resistentes à protease
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
BR112015015182A2 (pt) polipeptídeos do fator vii de ação curta
MX2019005600A (es) Molecula que induce la degradacion de la proteina ras y composiciones farmaceuticas.
AR106981A1 (es) Una composición antimicrobiana
CO6721014A2 (es) Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b